For U.S. Healthcare Professionals Only

For Healthcare Professionals


Positive Patient Experience

  • 90% of Carac® patients would use Carac® again
    • 9 out of 10 patients in a randomized study would choose to be re-treated with a Microsponge®-based 0.5% fluorouracil4
  • The most commonly reported adverse events were erythema (100%), erosion (81%), and dryness (71%)4

The Carac® clearing cycle

The Carac® clearing cycle: Baseline - 2 weeks - 4 weeks - 2 weeks post-treatment
Actual photos (photos have not been modified). Individual results may vary.

  • Once-a-day Carac® has a manageable tolerability profile
  • Irritation generally begins on day 4 and persists for the duration of therapy3
  • Irritation is generally localized to the site of application but may also include the eyes

Microsponge® is a registered trademark of Cardinal Health, Inc., its successors and assigns.

[Image of grass][Image of grass]
Carac® is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
IMPORTANT SAFETY INFORMATION
Carac® is contraindicated in women who are or may become pregnant, in patients with dihydropyrimidine dehydrogenase (DPD) enzyme deficiency, and in patients with known hypersensitivity to any of its components. In clinical trials, the most common drug-related adverse event was application site reaction (94.6%), which included: erythema, dryness, burning, erosion, pain, and edema. Some patients also experienced eye irritation (5.4%), including stinging and burning.
For more information, please see Full Prescribing Information for Carac®.